American Journal of Cardiology
Volume 104, Issue 10 , Pages 1362-1369 , 15 November 2009

Clinical Outcomes After Sirolimus-Eluting, Paclitaxel-Eluting, and Bare Metal Stents (from the First Phase of the Prospective Multicenter German DES.DE Registry)

  • Christoph A. Nienaber, MD, PhD

      Affiliations

    • University of Rostock, Rostock, Germany
    • Corresponding Author InformationCorresponding author: Tel: (+49) 0-381-494-7700; fax: (+49) 0-381-494-7702
    • ,
  • Ibrahim Akin, MD

      Affiliations

    • University of Rostock, Rostock, Germany
    • ,
  • Steffen Schneider, PhD

      Affiliations

    • Herzzentrum Ludwigshafen, Ludwigshafen, Germany
    • ,
  • Jochen Senges, MD, PhD

      Affiliations

    • Herzzentrum Ludwigshafen, Ludwigshafen, Germany
    • ,
  • Thomas Fetsch, MD

      Affiliations

    • Institut für klinische-kardiovaskuläre Forschung, München, Germany
    • ,
  • Ulrich Tebbe, MD, PhD

      Affiliations

    • Klinikum Lippe-Detmold, Detmold, Germany
    • ,
  • Stefan N. Willich, MD, PhD

      Affiliations

    • Institute of Social Medicine, Epidemiology and Health Economics, Charite Berlin, Berlin, Germany
    • ,
  • Jürgen Stumpf, MD

      Affiliations

    • Gemeinschaftspraxis Kardiologie und Angiologie, Dresden, Germany
    • ,
  • Georg V. Sabin, MD, PhD

      Affiliations

    • Elisabeth-Krankenhaus Essen, Essen, Germany
    • ,
  • Sigmund Silber, MD, PhD

      Affiliations

    • Kardiologische Gemeinschaftspraxis München, München, Germany
    • ,
  • Gert Richardt, MD, PhD

      Affiliations

    • Segeberger-Klinikum, Segeberg, Germany
    • ,
  • Karl-Heinz Kuck, MD, PhD

      Affiliations

    • Asklepios-Klinikum, Hamburg, Germany
    • ,
  • DES.DE Study Group

Received 10 May 2009 ,Revised 28 June 2009 ,Accepted 28 June 2009.

References 

  1. Silber S, Albertson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804–847
  2. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351
  3. Moses JW, Leon MB, Popma JJ, Fitzgerard PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  4. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947
  5. Stone GW, Ellis SG, Cox DA, Boam A, Cohen DJ, van Es GA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  6. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six- and twelve month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38–42
  7. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol. 2005;45:1135–1141
  8. Morice MC, Colombo A, Meier B, Serruys PW, Tamburino C, Guagliumi G, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006;295:895–904
  9. Galloe AM, Thuesen L, Kelbaek H, Rasmussen K, Hansen PR, Bligaard N, et al. Comparison of paclitaxel- and sirolimus-eluting stents in every day clinical practice: the SORT OUT II trial. JAMA. 2008;299:409–416
  10. Simonton CA, Brodie B, Cheek B, Krainin F, Metzger C, Hermiller J, et al. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry STENT group. J Am Coll Cardiol. 2007;50:1214–1222
  11. Williams DO, Abbott D, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover registry. Circulation. 2006;114:2154–2162
  12. Schömig A, Dibra A, Windecker S, Mehilli J, Suárez de Lezo J, Kaiser C, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1376–1380
  13. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative meta-analysis. Lancet. 2007;370:937–948
  14. Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006;48:32–36
  15. Morice MC, Serruys PW, Sousa E, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  16. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED. On-versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol. 2006;97:1478–1481
  17. Guagliumi G, Virmani R, Musumeci G, Motta T, Velsecchi O, Bonaldi G, et al. Drug-eluting versus bare metal coronary stents: long-term human pathology: finding from different coronary arteries in the same patient. Ital Heart J. 2003;4:713–720
  18. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112:270–278
  19. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation. 2004;109:701–705
  20. Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, et al. Long-term follow-up of incomplete stent apposition in patients who receive the sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation. 2003;108:2747–2750
  21. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel eluting coronary stents. N Engl J Med. 2007;356:998–1008
  22. Limpijankit T, Mehran R, Mintz GS, Dangas G, Lansky AJ, Kao J, et al. Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-II, and SCRIPPS-III). Am J Cardiol. 2003;92:315–318
  23. Nayak AK, Kawamura A, Nesto RW, Davies G, Jarbeau J, Pyne CT, et al. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J. 2006;70:1026–1109
  24. Walters DL, Harding SA, Walsh CR, Wong P, Pomerantsev E, Jang IK. Acute coronary syndrome is a common clinical presentation of in-stent restenosis. Am J Cardiol. 2002;89:491–494
  25. Sousa A, Costa R, Moreira AC, Cano M, Maldonado G, Costa RA, et al. Long-term clinical outcomes of drug-eluting stents in the real-world (DESIRE) registry. J Interv Cardiol. 2008;21:307–314
  26. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, et al. Long-term safety and efficacy of drug-eluting stents (Two-year results of the REAL (REgistro AngiopLastiche dellÈmilia Romagna) multicenter registry). Circulation. 2007;115:3181–3188

PII: S0002-9149(09)01321-6

doi: 10.1016/j.amjcard.2009.06.058

American Journal of Cardiology
Volume 104, Issue 10 , Pages 1362-1369 , 15 November 2009

Article Tools

* Image Usage & Resolution